Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Actinium Pharmaceuticals (ATNM) Return on Capital Employed (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Return on Capital Employed for 7 consecutive years, with 0.68% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed changed N/A to 0.68% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.68% through Dec 2025, changed N/A year-over-year, with the annual reading at 0.58% for FY2023, 19.0% down from the prior year.
  • Return on Capital Employed for Q4 2025 was 0.68% at Actinium Pharmaceuticals, up from 0.8% in the prior quarter.
  • The five-year high for Return on Capital Employed was 0.18% in Q2 2021, with the low at 0.85% in Q2 2025.
  • Average Return on Capital Employed over 5 years is 0.51%, with a median of 0.55% recorded in 2023.
  • The sharpest move saw Return on Capital Employed tumbled -35bps in 2023, then increased 4bps in 2024.
  • Over 5 years, Return on Capital Employed stood at 0.33% in 2021, then increased by 2bps to 0.33% in 2022, then plummeted by -108bps to 0.68% in 2023, then grew by 15bps to 0.57% in 2024, then fell by -19bps to 0.68% in 2025.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.68%, 0.8%, and 0.85% for Q4 2025, Q3 2025, and Q2 2025 respectively.